Cornea and Laser Eye Institute   Report issue

Academic/Hospital Phase 3
Founded: Teaneck NJ United States (1995)

Organization Overview

First Clinical Trial
2007
NCT00647699
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Cornea and Laser Eye Institute | Cornea and Laser Institute

Active Ingredients

Drugs in Phase 3 Trials (2)

ribavirin (virazole) (3 trials)

riboflavin (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Corneal Diseases (Phase 3)

Dilatation, Pathologic (Phase 3)

Keratoconus (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 2